Airway Therapeutics is developing a new class of biologics to break the injury cycle of inflammation for patients with respiratory and inflammatory diseases. The company is advancing AT-100 (rhSP-D), a recombinant human protein engineered to reduce inflammation and infection while modulating the immune response. AT-100 has received Orphan Drug Designation from both the U.S. Food and Drug Administration and the European Medicines Agency. Preclinical BPD research showed AT-100 prevented the onset of lung tissue damage and reduced inflammation and infection triggered by mechanical ventilation and oxygen support. Airway intends to use the financing to advance clinical development of AT-100 as a preventive treatment for bronchopulmonary dysplasia (BPD) in very preterm infants and to support preclinical work in influenza, RSV and cystic fibrosis. The company recently hired Alan S. Wolk as Chief Financial and Operating Officer and Uday Patel as Vice President of Regulatory Affairs and Quality. Airway Therapeutics develops a protein replacement therapy, AT-100, aimed at preventing and treating lung disease in vulnerable patients, beginning with premature infants. The company is based in Sharonville, Ohio, and is led by CEO Marc Salzberg with Paul V. Remsen as Vice President of Manufacturing. Airway has patent protection for its work and has received orphan designation status for AT-100 in bronchopulmonary dysplasia (BPD) in the US and the European Union, which provides a 7 and 12 year market exclusivity. The company recently secured $6.3M in bridge financing. Airway intends to use the funds to continue development of AT-100. The financing and regulatory incentives position the company to advance clinical development of its lead program. Airway Therapeutics is a Sharonville, Ohio-based biotechnology company focused on preventing bronchopulmonary dysplasia (BPD) in extremely premature infants. Its lead product, AT-100, is a recombinant human surfactant protein D intended to be used in addition to commercial surfactant to prevent infection and lung damage. Pre-clinical data reported by the company suggest AT-100 more effectively prevents infection and lung injury than the current standard of care. Both the US Food and Drug Administration and European regulators have granted AT-100 orphan designation. Led by CEO Marc Salzberg, MD, the company intends to use its recent financing to continue development of AT-100.

Total raised

$26M

Funding rounds

3

Latest round

Series C

Latest activity

Jan 2020